72,992 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Acquired by Rothschild Investment LLC

Rothschild Investment LLC acquired a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 72,992 shares of the company's stock, valued at approximately $2,088,000. Rothschild Investment LLC owned about 0.16% of Pacira BioSciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. ICA Group Wealth Management LLC purchased a new stake in Pacira BioSciences during the 4th quarter valued at approximately $30,000. GAMMA Investing LLC grew its holdings in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock worth $38,000 after purchasing an additional 932 shares during the last quarter. Park Place Capital Corp purchased a new position in shares of Pacira BioSciences in the 2nd quarter valued at approximately $46,000. Innealta Capital LLC purchased a new stake in Pacira BioSciences during the 2nd quarter valued at about $50,000. Finally, Quadrant Capital Group LLC grew its stake in Pacira BioSciences by 61.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company's stock valued at $78,000 after purchasing an additional 885 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the company. HC Wainwright reduced their target price on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a report on Monday, August 12th. Needham & Company LLC cut their price target on Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. JPMorgan Chase & Co. restated an "underweight" rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Truist Financial lowered Pacira BioSciences from a "buy" rating to a "sell" rating and decreased their price target for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. Finally, Barclays lowered Pacira BioSciences from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $24.78.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 5,012 shares of the company's stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total transaction of $143,192.84. Following the transaction, the insider now owns 44,569 shares in the company, valued at $1,273,336.33. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, SVP Lauren Riker sold 3,970 shares of Pacira BioSciences stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total value of $114,018.40. Following the transaction, the senior vice president now owns 38,075 shares in the company, valued at approximately $1,093,514. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jonathan Slonin sold 5,012 shares of the business's stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total transaction of $143,192.84. Following the completion of the transaction, the insider now owns 44,569 shares in the company, valued at approximately $1,273,336.33. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 11,176 shares of company stock worth $136,240 and have sold 22,095 shares worth $621,118. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Trading Up 1.3 %

NASDAQ:PCRX traded up $0.20 during trading hours on Friday, hitting $15.56. The stock had a trading volume of 702,297 shares, compared to its average volume of 872,313. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $36.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. The company has a market cap of $724.26 million, a price-to-earnings ratio of 10.88 and a beta of 0.88. The business's 50 day moving average is $19.50 and its 200-day moving average is $25.61.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million during the quarter, compared to analysts' expectations of $173.31 million. Sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.26 EPS for the current fiscal year.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.